Rationale documents

• Amphotericin B v 3.0 (26 June 2025)
• Anidulafungin vs. Candida v 5.0 (26 June 2025)
• Caspofungin vs Candida - there is no caspofungin RD and no specific caspofungin breakpoints. Use anidulafungin and micafungin as markers for caspofungin susceptibility where isolates "S" to  both anidulafungin and micafungin are considered susceptible to caspofungin. Similarly, for C. parapsilosis isolates "I" for anidulafungin and micafungin then can be reported "I" for caspofungin.
• Fluconazole vs. Candida v 3.0 (2020)
• Flucytosine v 1.0 (22 July 2025)
• Isavuconazole vs. Aspergillus v 3.0 (26 June 2025)
• Itraconazole v 3.0 (2021)
• Micafungin vs. Candida v 4.0 (26 June 2025)
• Posaconazole v 3.0 (2020)
• Rezafungin v 2.0 (26 June 2025)
• Voriconazole v 4.0 (2020) 

For previous versions of documents, see the document archive.

Template for producing a Rationale Document

Download  (26 June 2014)